- Conditions
- Breast Cancer
- Interventions
- Sentinel Node Biopsy
- Procedure
- Lead sponsor
- University of Arkansas
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 699 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1998 – 2011
- U.S. locations
- 1
- States / cities
- Little Rock, Arkansas
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–30
of 30
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Breast Cancer
- Interventions
- filgrastim, capecitabine, celecoxib, cyclophosphamide, docetaxel, doxorubicin hydrochloride, gene expression analysis, polymorphism analysis, protein expression analysis, reverse transcriptase-polymerase chain reaction, imaging biomarker analysis, immunohistochemistry staining method, laboratory biomarker analysis, pharmacogenomic studies, dynamic contrast-enhanced magnetic resonance imaging, needle biopsy, neoadjuvant therapy, radiomammography, ultrasound imaging
- Biological · Drug · Genetic + 2 more
- Lead sponsor
- University of Nebraska
- Other
- Eligibility
- 19 Years to 120 Years · Female only
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2009
- U.S. locations
- 1
- States / cities
- Omaha, Nebraska
- Conditions
- Breast Cancer
- Interventions
- therapeutic autologous dendritic cells, aromatase inhibition therapy, cyclophosphamide, doxorubicin hydrochloride, paclitaxel, tamoxifen citrate, gene expression analysis, protein expression analysis, reverse transcriptase-polymerase chain reaction, immunoenzyme technique, immunohistochemistry staining method, laboratory biomarker analysis, adjuvant therapy, biopsy, conventional surgery, neoadjuvant therapy, radiation therapy
- Biological · Drug · Genetic + 3 more
- Lead sponsor
- University of Nebraska
- Other
- Eligibility
- 19 Years to 120 Years · Female only
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2010
- U.S. locations
- 2
- States / cities
- Tampa, Florida • Omaha, Nebraska
- Conditions
- Carcinoma, Intraductal, Noninfiltrating
- Interventions
- Pembrolizumab, Intralesional mRNA 2752
- Drug · Biological
- Lead sponsor
- Laura Esserman
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2026
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Breast Cancer, Cancer of the Breast
- Interventions
- LS301, Cancer Vision Goggles and standard fluorescence imaging systems, Surgery
- Drug · Device · Procedure
- Lead sponsor
- Samuel Achilefu
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Breast Cancer, HER2-positive Breast Cancer, Triple Negative Breast Cancer
- Interventions
- Neoadjuvant Chemotherapy, Radiation Therapy, MRI, Breast Cancer Surgery, Biopsy, Biospecimen collection
- Drug · Radiation · Procedure
- Lead sponsor
- Ohio State University Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 84 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Columbus, Ohio